The Most Advanced DNA-Encoded
Library Technology
Overcoming the limitations of unbiased screening technologies
Until now, there has been no technology that enabled serendipitous discoveries through unbiased screening by delivering hits fast, cost-effectively and with high quality. Serengen’s breakthrough DNA-Encoded Library (DEL) Technology eliminates the bottlenecks and major cost drivers of established unbiased screening technologies. For the first time, truly druglike DELs can be produced and screened with high speed, cost efficiency and excellent hit quality.
LIMITATION-FREE CHEMISTRY
DELIVERS TRULY DRUGLIKE HITS
MYRIADS OF CHEMICAL REACTIONS
CREATE DIVERSITY
NOVEL CHEMICAL SPACE
ADDRESSES NEW TARGETS
We apply modern screening compound design to DNA-encoded libraries by synthesising the central scaffolds on DNA and decorating them on their exit vectors. By venturing new chemical spaces, you can address new biological targets.
DOUBLE
FIDELITY
Double purification removes by-products and artefacts and reduces false positives. Concentration adjustment reduces the risk
of false negatives.
QUALITY
TRUMPS
QUANTITY
Limitation-free chemistry
delivers truly druglike hits
Myriads of chemical reactions
create diversity
Novel chemical space
addresses new targets
Double purification removes by-products and artefacts and reduces false positives. Concentration adjustment reduces the risk
of false negatives.
Double
Fidelity
We apply modern screening compound design to DNA-encoded libraries by synthesising the central scaffolds on DNA and decorating them on their exit vectors. By venturing new chemical spaces, you can address new biological targets.
Quality trumps Quantity
DELs for drug discovery are in!
We avoid redundancies and thus reduce costs and time of hit follow-up.
ULTRA-LARGE DELS ARE OUT,
DELS FOR DRUG DISCOVERY ARE IN!
We avoid redundancies and thus reduce costs and time of hit follow-up.
ENABLING SERENDIPITY BY REDUCING COSTS AND FAILURE
However, traditional DELs mostly contain non-druglike compounds, Poor hit quality typically leads to failures in lead generation or optimisation. This is a major problem because hit quality is the most important success factor in early drug discovery.
At Serengen, we overcome the limitations of traditional DELs by addressing three key points: (I) chemistry, (II) design, and (III) approach.
As a result, our technology increases the probability
of serendipitous discoveries with high hit quality and
reduces costs and failure in early drug discovery.
our experts!
+49 (0)231 999 50 902
We are happy to answer any question!
our experts!
+49 (0)231 999 50 902
We are happy to answer any question!
*Required
I agree that the information I supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679.
